SMi is proud to present their inaugural conference...
Cancer Vaccines 2012
19th & 20th September 2012, London
About the Conference
SMi's inaugural conference on Cancer Vaccines will provide attendees with a complete view of the cancer immunotherapy field. Focusing on the discovery of new vaccines, developments in target identification and vaccine delivery strategies, this informative event will bring together key opinion leaders in the field to provide attendees with an indepth look into current advances in cancer vaccines.
The event will present itself as a perfect forum for learning about new advances in the field, presenting attendees with the latest information on technogical and regulatory updates in the field. SMi's Cancer Vaccines 2012 will explore the use of biomarkers in cancer immunotherapy developments and will provide the perfect platform for discussions into regulatory challenges faced in cancer developments as well as strategies to improve success in clinical trials.
With senior industry representatives presenting on their own exepriences and referring to case studies, success stories and failures, this event promises to be a unique forum for problem-solving debate and idea-sharing discussion.
Interested in speaking at the conference? Contact the Conference Producer.
For sponsorship and exhibition opportunities, Contact our Sponsorship Department
Why should you attend this event?
• Learn about and consider the issues within novel vaccine discovery • Discuss methods and strategies for efficient target selection • Consider developments in vaccine delivery strategies • Understand the use of biomarkers in cancer immunotherapy • Debate the importance of overcoming immune supression in the tumor microenvironment • Evaluate manufacturing, regulatory and commercial challenges • Develop ideas and network with key industry professionals
Hear keynote addresses from:
Our Expert Speaker Line-up includes:
Vincent Brichard, Senior Vice President, GSK Biologicals Oliver Wilbert, Senior Director, Merck-Serono Nicholas Valiante, Head of Immunology, Novartis Jerome Galon, Director of Research, INSERM Sonia Quaratino, Senior Medical Director, Merck-Serono Athansios Papadopoulos, Senior Medical Advisor, Novartis Matthew Albert, Director of Immunology, Institut Pasteur Philip Ashton-Rickardt, Chair in Immunology, Imperial College London Karl-Josef Kallen, Chief Scientific Officer, CureVac Eric Leire, CEO, DanDrit Biotech Christian Ottensmeier, Professor in Experimental Cancer Medicine, University of Southampton Rohit Lal, Consultant Oncologist, Guy's Hospital
ChemiFast is a new chemiluminescence substrate that is sensitive and produces a signal that is stable for up to 24 hours, making i....
The KingFisher Duo nucleic acid purification system is a low- to medium-throughput package, which includes the KingFisher magnetic....
The new Human Stemcca
The rProtein A GraviTrap
© 2013 Bioscreening.com